Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
Compose a Response to This Article
Other responses
No responses have been published for this article.
